4.7 Article

Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Rural representation of the surveillance, epidemiology, and end results database

Joshua Herb et al.

Summary: SEER data is widely used for studying cancer disparities in rural and urban areas but there is little research on how well rural areas covered by SEER represent the broader rural United States. Results show that rural SEER and non-SEER counties have similar demographics and cancer screening rates. However, patients in rural SEER regions have shorter travel times to cancer care facilities compared to those in rural non-SEER regions.

CANCER CAUSES & CONTROL (2021)

Article Oncology

Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials

Ryan W. Huey et al.

Summary: The study surveyed the economic burden and financial toxicity in cancer patients participating in clinical trials, revealing a high economic burden with most of the out-of-pocket costs being nonmedical. Patients with lower income and who traveled farther experienced worse financial toxicity, while non-White or Hispanic patients were more likely to encounter unexpected medical costs.

ONCOLOGIST (2021)

Article Oncology

Disparities in phase 1 cancer clinical trial enrollment

Subha Perni et al.

Summary: The study found disparities in phase 1 versus phase 2/3 trial enrollment, with Black, Hispanic/Latino, and male patients being less likely to enroll in phase 1 trials compared to White patients. The findings suggest a need for targeted interventions to improve access to and education about phase 1 trials for Black and Hispanic/Latino patients.

CANCER (2021)

Review Oncology

Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials

D. Ross Camidge et al.

Summary: This study assessed the demographic representation in Phase I trials of biopharmaceutical oncology agents published in 2019. The results showed that the population in these trials was predominantly White/Caucasian, with minimal representation of minority groups. Further research is needed to understand and address barriers to participation among under-represented groups.

FUTURE ONCOLOGY (2021)

Article Oncology

Phase I trials as valid therapeutic options for patients with cancer

Jacob J. Adashek et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Article Surgery

Does Enrollment in Cancer Trials Improve Survival?

Christopher J. Chow et al.

JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2013)

Article Oncology

Barriers to Recruitment of Rural Patients in Cancer Clinical Trials

Shamsuddin Virani et al.

JOURNAL OF ONCOLOGY PRACTICE (2011)

Article Public, Environmental & Occupational Health

Awareness of the Tuskegee Syphilis Study and the US presidential apology and their influence on minority participation in biomedical research

Ralph V. Katz et al.

AMERICAN JOURNAL OF PUBLIC HEALTH (2008)

Article Medicine, General & Internal

Participants in phase 1 oncology research trials - Are they vulnerable?

Justine Seidenfeld et al.

ARCHIVES OF INTERNAL MEDICINE (2008)

Article Medicine, General & Internal

Participation in cancer clinical trials - Race-, sex-, and age-based disparities

VH Murthy et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)